Repositioning Candidate Details
| Candidate ID: | R0992 |
| Source ID: | DB06360 |
| Source Type: | investigational |
| Compound Type: | biotech |
| Compound Name: | Lucatumumab |
| Synonyms: | Lucatumumab |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | -- |
| CAS Number: | 903512-50-5 |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified). |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. Based on preclinical data, HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies. |
| Targets: | Tumor necrosis factor receptor superfamily member 5 |
| Inclusion Criteria: | Target associated |
